Development, preclinical, and early clinical data on the GIP/GLP-1 receptor agonist tirzepatide Among the GIP/GLP-1 receptor agonists, tirzepatide (LY3298176) is the compound that is the most advanced in development and the first substance in this class that has received approval for the therapy of T2D by the FDA in May 2022 (manufacturer Eli Lilly Comp., trade name Mounjaro ) (5355)
It shows that members who used the Noom GLP-1 Companion app most frequently achieved greater weight lossand a higher rate of medication program persistencecompared with less-engaged peers
Her doctor fought to keep her on the GLP-1 agonist, the category that includes weight loss and Type 2 diabetes drugs Ozempic, Wegovy, Mounjaro, and Zepbound
Long-term weight management may help improve: Blood pressure Cholesterol levels Energy and stamina Sleep quality Mobility and joint comfort Confidence and self-esteem Overall metabolic health Our team is committed to providing compassionate, medically supervised care that supports patients throughout every stage of their journey
